Brief: PhaseRx says advances product pipeline for treatment of rare genetic liver diseases
21/06/2016 13:00
June 21 (Reuters) - Phaserx Inc PZRX.O -
* Phaserx advances product pipeline for treatment of rare
genetic liver diseases
* Developing drugs to replace missing or defective enzyme
using intracellular enzyme replacement therapy
* Expects to generate Phase 2A (single-dose) and 2B
(repeat-dose) clinical proof-of-concept data for PRX-OTC in 2018
Source text for Eikon: ID:nPnQK3Jla
Further company coverage: PZRX.O
(Bengaluru Newsroom: +1-646-223-8780)
Recent news on PZ Wind Down
See all newsBrief: Phaserx, Roivant Enter Into Asset Purchase Agreement
Brief: Phaserx Says Auction For Nearly All Of Co's Assets Was Held, But Did Not Conclude
Brief: Phaserx Revokes Proposed Distribution Record Date
Brief: PhaseRx Receives Decision From Nasdaq Hearings Panel For Continued Listing Of Shares
Brief: Phaserx Commences Voluntary Chapter 11 Bankruptcy Protection Proceeding